Pathophysiology and treatment of the dyslipidemia of insulin resistance
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Insulin resistance, and the compensatory hyperinsulinemia that results, has been linked to a host of defects including glucose intolerance, diabetes, hypertension, dyslipidemia, endothelial dysfunction, impaired fibrinolysis, and subclinical inflammation. Patients with this metabolic syndrome have a markedly increased risk for the development of atherothrombotic cardiovascular disease. The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol. Management of this dyslipidemia typically involves a dual approach. Lifestyle modification is an essential component of any successful treatment plan, but alone is usually insufficient to correct these lipoprotein abnormalities. Medications that diminish insulin resistance and directly alter lipoproteins are also necessary in the majority of cases. Combinations of therapeutic agents are often required to optimize attainment of treatment goals.
- Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998, 339:229–234. CrossRef
- Dagogo-Jack S, Santiago JV: Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Int Med 1997, 103:1802–1817. CrossRef
- Eschwege E, Richard JL, Thibult N, et al.: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris prospective study, ten years later. Horm Metab Res 1985, 15(suppl): 41–46.
- Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. New Engl J Med 1996, 334:952–957. CrossRef
- Haffner SM, Miettinen H: Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997, 103:152–162. An excellent summary of the relationships between IR and the major cardiovascular risk factors. CrossRef
- Reaven GM: Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991, 121:1283–1288. CrossRef
- Rett K: The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obes Metab 1999, 1(suppl 1):8–6. CrossRef
- Festa A, D’Agostino, Jr. R, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000, 102:42–47.
- Mokdad AH, Serdula Mk, Dietz WH, et al.: The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999, 282:1519–1522. CrossRef
- Must A, Spradano J, Coakley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523–1529. CrossRef
- Kwiterovich, Jr. PO: The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000, 86(12 Suppl 1):5–10. A concise review of both normal and abnormal lipoprotein metabolism. CrossRef
- Goldberg RB, Capuzzi D: Lipid disorders in type 1 and type 2 diabetes. Clin Lab Med 2001, 21:147–171.
- Superko HR: Small, dense low-density lipoprotein subclass pattern B: issues for the clinician. Curr Atheroscler Rep 1999, 1:50–57. A great review of small, dense LDL-C by one of the leaders in the field. CrossRef
- O’Keefe, Jr. JH, Miles JM, Harris WH, et al.: Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc 1999, 74:171–180. Another outstanding review of the links between IR and CVD. Drug therapy is reviewed in some detail as well. CrossRef
- Knopp RH: Current concepts in dietary therapy for dyslipidemia. In Mediguide to Heart Diseases. Edited by AM Gotto, Jr. New York: Lawrence DellaCorte; 2000, 3:1–8. A succinct, evidence-based summary of the effects of various diets on dyslipidemia.
- O’Keefe, Jr. JH, Harris WS: From inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc 2000, 75:607–614.
- Shikany JM, White Jr. GL: Dietary guidelines for chronic disease prevention. South Med J 2000, 93:1138–1151.
- Lynch J, Helmrich SP, Lakka TA, et al.: Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. Arch Int Med 1996, 156:1307–1314. CrossRef
- Henry RR: Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Int Med 1996, 124(suppl 1):97–103.
- Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Arch Int Med 1998, 158:1855–1867.
- Davidson MH, Hauptman J, DiGirolamo M, et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235–242. CrossRef
- Heymsfield SB, Segal KR, Hauptman J, et al.: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Int Med 2000, 160:1321–1326. CrossRef
- Lindgarde F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish multimorbidity study. J Int Med 2000, 248:245–254. CrossRef
- Grosskopf I, Ringel Y, Charach G, et al.: Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. Diabetes Care 1997, 20:1598–1602. CrossRef
- Charles MA, Morange P, Eschwege E, et al.: Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO 1 Study. Diabetes Care 1998, 21:1967–1972. CrossRef
- Mather KJ, Verma S, Anderson TJ: Improved endothelial function with metformin in type 2 diabetes mellitus. Circulation 2001, 37:1344–1350.
- Defronzo RA: Treatment of type 2 diabetes mellitus: a sound approach based upon its pathophysiology. Lawrenceville: Academy of Medicine of New Jersey; 2001:21–23.
- Parulkar AA, Pendergrass ML, Granda-Ayala R, et al.: Nonhypoglycemic effects of thiazolidinedones. Ann Int Med 2001, 134:61–71. Explores the many benefits of this class of medication on IR beyond improved glucose control.
- Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153. A landmark study in CVD prevention whose implications will be debated well into the future. CrossRef
- Hansson L, Lindholm LH, Niskanenn L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) Randomized Trial. Lancet 1999, 353:611–616. CrossRef
- Baron AD: Vascular reactivity. Amer J Cardiol 1999, 84:25J-27J. CrossRef
- Petrie JR, Ueda S, Webb DJ, et al.: Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996, 93:1331–1333.
- Schmidt MI, Duncan BB, Sharrett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649–1652. CrossRef
- Haffner SM, Alexander CM, Cook TJ, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Int Med 1999, 159:2661–2667. CrossRef
- Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the west of Scotland Coronary Prevention Study. Circulation 2001, 103:357–362.
- Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341:498–511. CrossRef
- Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992, 85:37–45.
- Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410–418. CrossRef
- Effect of Fenofibrate on Progression of Coronary Artery Disease in Type 2 Diabetes: The Diabetes Atherosclerosis Intervention Study. Lancet 2001, 357:905–910.
- Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM: Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep 2000, 2:64–71. CrossRef
- Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. JACC 1986, 8:1245–1255.
- Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405–418. CrossRef
- Elam MB, Hunninghake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. the ADMIT Study: a randomized trial. JAMA 2000, 284:1263–1270. CrossRef
- Pathophysiology and treatment of the dyslipidemia of insulin resistance
Current Cardiology Reports
Volume 3, Issue 5 , pp 416-423
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links